The logic behind the approach builds on a decade of epilepsy gene therapy. Most experimental genetic treatments for seizures work by boosting the potassium conductance of neurons, effectively adding brake pedals to cells that fire too readily. Adeno-associated virus vectors, the workhorses of modern neurological gene therapy, are used to smuggle engineered ion channel genes into a circumscribed patch of brain tissue, where they render hyperexcitable neurons less likely to ignite pathological activity. Because seizures and spreading depolarization frequently co-occur, the Moscow group, led by Evgeny Nikitin and Lyudmila Vinogradova, asked a question that had not been systematically addressed: what happens to spreading depolarization when you give neurons extra potassium conductance?

The channel they chose was KCa3.1, encoded by the gene KCNN4. Unlike voltage-gated potassium channels, KCa3.1 opens in response to intracellular calcium, which surges whenever a neuron fires vigorously. This makes the channel a self-regulating safety valve: the harder a cell works, the more the channel opens, letting potassium ions flow out and pulling the membrane potential back toward rest. Earlier work by the same team had shown that overexpressing KCNN4 in principal neurons produces an anti-seizure effect without degrading the cells’ ability to encode information, a crucial consideration for any therapy that must leave normal brain function intact. Whether the same manipulation would influence the massive, synchronized ionic collapse of spreading depolarization was an open question.

To find out, the researchers injected an AAV vector carrying KCNN4 into the neocortex of mice and then attacked the problem from three technical directions. Patch-clamp electrophysiology allowed them to record the membrane potential of individual neurons as a depolarization wave swept past. Functional imaging in acute brain slices, using voltage- and calcium-sensitive indicators, revealed how the wave propagated through the cortical network. And direct-current-coupled field potential recordings captured the full signature of spreading depolarization in vivo, including in awake, non-anesthetized animals, a demanding preparation that avoids the confounding effects of anesthetics on cortical excitability.

The results were striking. KCNN4 expression reduced the amplitude of the spreading depolarization several-fold, an effect documented both in slices and in the intact cortex of freely moving mice. The wave also traveled more slowly through treated tissue, as measured by the timing of its arrival at recording sites in the slices. Slower propagation matters clinically: the damage inflicted by spreading depolarization after stroke or traumatic brain injury is thought to scale with the depth and duration of the ionic disruption, so a wave that is smaller and slower should, in principle, be less injurious. In patients with malignant stroke or decompressive craniectomy, spreading depolarizations detected with subdural electrodes are associated with worse outcomes, making amplitude and propagation speed attractive therapeutic targets.

The gene therapy also reshaped the aftermath of the wave. Spreading depolarization imposes a period of profound neuronal silencing, during which epileptiform activity is temporarily abolished. Paradoxically, in the KCNN4-treated slices this suppression ended sooner, with seizure-like events reappearing earlier than in control tissue. The finding highlights a subtle and clinically important trade-off. Some evidence suggests that spreading depolarization itself can act as an innate antiseizure mechanism, terminating seizures by short-circuiting electrical propagation across the cortex. A therapy that shrinks the depolarization wave might therefore, in some circumstances, shorten the very silencing that ends a seizure. The authors flag this as a side effect that any potassium-conductance-enhancing gene therapy for epilepsy will need to weigh.

Delving into the mechanism, the team documented a calcium rebound that follows spreading depolarization when epileptiform activity resumes. As neurons recover and begin firing again, intracellular calcium climbs steeply, and this rebound can feed back into the intensity of the recovered activity. In KCNN4-expressing neurons, the channel’s calcium sensitivity turns this rebound to advantage: the rising calcium opens the overexpressed KCa3.1 channels, which generate a potassium-mediated afterhyperpolarization that counterbalances the depolarizing drive. In effect, the therapy converts a vicious cycle, in which calcium influx amplifies excitability, into a negative feedback loop that restrains it. This cell-autonomous quality, where each neuron polices its own excitability, distinguishes the approach from drugs that act globally and indiscriminately.

The technical execution relied on a mature toolkit. AAV vectors have become the dominant platform for nervous system gene therapy because they are relatively safe, transduce neurons efficiently, and support long-term expression. The team’s vector design and cloning were performed in-house, and the imaging data were processed with supervised calcium event detection tools developed by the group. The in vivo experiments in awake animals are particularly notable, since spreading depolarization amplitude and threshold can be altered by anesthesia, and recordings from non-anesthetized mice provide the most physiologically relevant readout of how the therapy would behave in a clinical setting.

The broader significance lies in the intersection of two therapeutic frontiers. Gene therapy for epilepsy is advancing rapidly, with engineered potassium channels, optogenetic tools, and on-demand dynorphin-based systems all showing efficacy in rodent models, and at least one company has raised substantial funding to develop a single-dose gene therapy for focal refractory epilepsy. Spreading depolarization, meanwhile, has emerged as a therapeutic target in its own right, with ketamine trials in acute brain injury aiming to suppress the waves pharmacologically. The new study connects these threads, demonstrating that a single genetic manipulation can simultaneously dampen seizures and attenuate spreading depolarization, while also revealing the unexpected interaction between the two phenomena.

Caveats remain before any translation to patients. The work is a proof of principle in rodents, and the authors themselves note that reducing spreading depolarization via increased potassium conductance may carry the paradoxical risk of prolonging seizure activity by removing a natural braking mechanism. The dosing of channel expression, the durability of the effect, and the behavior of the therapy in injury models of stroke and trauma all await further study. Still, the demonstration that a targeted viral gene delivery can measurably shrink one of the brain’s most violent electrical events opens a concrete path toward treating disorders, from migraine to stroke, that are complicated by spreading depolarization, using nothing more than the neurons’ own molecular machinery.

Subject of Research: Viral gene therapy targeting spreading depolarization via KCa3.1 potassium channel expression

Article Title: Local targeted suppression of neocortical spreading depolarization amplitude by viral expression of KCa3.1 channels

Article References: Oblasov, I. A., Smirnova, M. P., Borodinova, A. A., Zuzina, A. B., Smirnov, I. A., Balaban, P. M., Vinogradova, L. V., & Nikitin, E. S. (2026). Local targeted suppression of neocortical spreading depolarization amplitude by viral expression of KCa3.1 channels. Gene Therapy. https://doi.org/10.1038/s41434-026-00645-x

Image Credits: AI Generated

DOI: 10.1038/s41434-026-00645-x

Keywords: spreading depolarization, gene therapy, KCa3.1, KCNN4, adeno-associated virus, epilepsy, migraine, stroke, potassium channels, neocortex, electrophysiology, afterhyperpolarization